IMR Press / FBL / Volume 25 / Issue 3 / DOI: 10.2741/4818

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Forsythiaside A alleviates renal damage in adriamycin-induced nephropathy
Show Less
1 Department of Nephrology, Rui’an people’s Hospital and The Third Affiliated Hospital of Wenzhou Medical University. Rui’an, Zhejiang, 325200, P. R. China
Front. Biosci. (Landmark Ed) 2020, 25(3), 526–535; https://doi.org/10.2741/4818
Published: 1 January 2020
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)
Abstract

Nephrotic syndrome (NS) is a common urinary system disease that carries a poor progrnosis due to nonresponsivess to current treatments. The purpose of this study was to investigate the therapeutic effects of Forsythiaside (FA) in a rat model of adriamycin-induced nephropathy (AN). Compared with control group, FA treatment significantly reduced proteinuria, serum creatinine and urea nitrogen levels and reduced the number of apoptotic cells in the kidneys. FA alleviated Adr induced renal injury, and increased the sactivity of superoxide dismutase (SOD), while decreasing malondialdehyde (MDA) and lactate dehydrogenase (LDH) in the serum. In addition, FA, in a dose-dependent manner, decreased the levels of NF-kappaBp65/MIP-2 in the kidenys, reduced the serum level of pro-inflammatory cytokines (IL-6, IL-1 β and TNF-alpha), and increased the survival rate of Adr treated rats. Taken together, the results show that FA alleviates renal dysfunction in adriamycin-induced nephropathy rats.

Keywords
Forsythiaside A
Adriamycin
Nephropathy
p65 NF-kappaB
MIP-2
Figures
Figure 1
Share
Back to top